DYAI Aug 2024 2.500 call
- GuruFocus.com
Dyadic International Inc (DYAI) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review ...
Explore key financial outcomes and strategic initiatives as Dyadic International Inc navigates through Q1 2024, focusing on innovation and market expansion.
- GlobeNewswire
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
Human Health Sector Final Clinical Study Report has been issued for the First-In-Human Phase 1 clinical trial demonstrating safety and antibody response for DYAI-100, a recombinant protein receptor binding domain booster vaccine candidate for protection against COVID-19 infectionEntered into several fully funded vaccine and antibody projects covering more than twelve targets, five of which are funded by two of the top ten pharmaceutical companiesSuccessfully expressed a H1N1 influenza antigen in
- GlobeNewswire
Dyadic to Attend Industry and Investor Events in May
JUPITER, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, today announced that its management will be attending the following industry and investor ev
